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Abstract
Background
Evaluations of the impact of interventions for resource allocation purposes commonly focus
on health status. There is, however, also concern about broader impacts on wellbeing and,
increasingly, on a person's capability. This study aims to compare the impact on health sta-
tus and capability of seven major health conditions, and highlight differences in treatment
priorities when outcomes are measured by capability as opposed to health status.
Methods
The study was a cross-sectional four country survey (n = 6650) of eight population groups:
seven disease groups with: arthritis, asthma, cancer, depression, diabetes, hearing loss,
and heart disease and one health population ‘comparator’ group. Two simple self-complete
questionnaires were used to measure health status (EQ-5D-5L) and capability (ICECAP-A).
Individuals were classified by illness severity using condition-specific questionnaires. Effect
sizes were used to estimate: (i) the difference in health status and capability for those with
conditions, relative to a healthy population; and (ii) the impact of the severity of the condition
on health status and capability within each disease group.
Findings
5248 individuals were included in the analysis. Individuals with depression have the great-
est mean reduction in both health (effect size, 1.26) and capability (1.22) compared to the
healthy population. The effect sizes for capability for depression are much greater than for
all other conditions, which is not the case for health. For example, the arthritis group effect
size for health (1.24) is also high and similar to that of depression, whereas for the same
arthritis group, the effect size for capability is much lower than that for depression (0.55). In
terms of severity within disease groups, individuals categorised as 'mild' have similar capa-
bility levels to the healthy population (effect sizes <0.2, excluding depression) but lower
health status than the healthy population (0.4).
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Conclusion
Significant differences exist in the relative effect sizes across diseases when measured by
health status and capability. In terms of treating morbidity, a shift in focus from health gain to
capability gain would increase funding priorities for patients with depression specifically and
severe illnesses more generally.
Introduction
All health care systems in all societies are constrained by the availability of resources. All have
to set priorities and, whilst there are numerous suggestions about how this should be done [1],
importance is generally attached to obtaining good outcomes from interventions, often along-
side a comparison of cost in an economic evaluation. The question of what constitutes a good
outcome is fundamental. Commonly it is equated with improvements in health status. In
health economics this is measured through instruments weighted using population preferences
that are known as health related utility. Health related utility allows for the comparison of
diverse health states on a cardinal (interval or ratio) scale anchored at utility = 1 (best possible
health) and utility = 0 (death) representing people’s preferences for different states of health-
related quality of life [2].
There are, however, arguments for exploring measures of outcome including subjective
wellbeing [3] and capability [4–8]. Broader outcome measures facilitate evaluation across pro-
gramme areas, such as social care, public health, crime and education as well as health care.
Measures of subjective wellbeing essentially focus on happiness but an exclusive focus upon
this can be criticised as too limiting, as hedonic adaptation results in the disregard of serious
limitations to a person’s abilities [9]. The focus of the capability approach is on “not just what a
person actually ends up doing, but also on what she is in fact able to do, whether or not she
chooses to make use of that opportunity” [10]. There has been a notable upsurge in interest in
applying the approach to resource allocation decisions in health care [5,11–17], as well as
increasing numbers of empirical studies employing the approach [18–21].
A change in focus—from health gain to capability gain—would potentially raise the priority
of those activities that most affect the capability and, conversely, reducing the priority of activi-
ties which have little or no effect upon capability. This would therefore lead to a reallocation of
healthcare resources. The objective of the present study is to compare the effect on health status
and capability of major health conditions and therefore to determine whether a shift in evalua-
tive focus from health status to capability is likely to have a major impact upon resource alloca-
tion priorities.
Methods
Study Design and Participants
The study uses data from a Multi Instrument Comparison (MIC) cross sectional survey of indi-
viduals in eight health categories (http://www.aqol.com.au). The survey was conducted in six
countries of which the four English speaking nations were chosen for the present analyses (as
the choice of these countries did not raise problems associated with translation). Details of the
two countries (Germany and Norway) excluded from this study can be found elsewhere [22].
As well as a healthy population, seven broad disease groups were targeted, viz, persons with
arthritis, asthma, cancer, diabetes, depression, hearing loss, and heart disease. These disease
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areas were chosen to represent major chronic conditions that result in significant burden of
disease in developed countries [23,24].
Instruments
Condition-specific instruments were used to measure the severity of each condition. Two
instruments were selected to measure health status and capability. To this end, the measures
were selected as (i) being short, simple measures often applied in clinical trials and regulatory
decision making, and (ii) because both allow a meaningful index to be attributed to the level of
health status/capability that is measured.
Health: EQ-5D-5L. The EQ-5D-5L is an updated version of the original EQ-5D-3L
generic measure of health status [25,26]. The instrument is recognised as one of the most
widely used generic measures of health status to generate quality-adjusted life-years (QALYs)
[27]. It has been translated into 169 different languages. EQ-5D data are routinely collected in
some countries as well as being used to inform healthcare decision-making [28]. The instru-
ment has five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/
depression). Each dimension has five response levels (http://www.euroqol.org) [29]. Once a
response level for each dimension is selected by the patient, general population values can then
be attached to the patient’s current health state. These general population values are derived
from previous time trade-off exercises with members of the UK general population to elicit the
strength of preference for different health states over others [30,31]. The use of population val-
ues (which represent the average value of a sample of the general public), as opposed to patient
values (which represent the value placed on a state by the individual in that state), is the pre-
ferred approach by health guidance bodies such as the National Institute for Health and Care
Excellence (NICE) [32]. Population values are considered by some as a more appropriate
method because it might allow for greater objectivity across disease areas and it incorporates
the valuation of health benefits by citizens/taxpayers [33]. The general population approach to
valuing health states means that all possible health states across a health service can be, in the-
ory, compared to one another. Preliminary general population values for the EQ-5D-5L have
been developed from the three level versions [31], as research is currently ongoing to derive
new value sets for the five level version. The measure is anchored at 1 (best health) and 0
(death), with a minimum value of -0.594 for the UK value set. Values thus range from -0.594 to
1, with negative values representing states considered worse than being dead. There has been
one major study to date assessing the validity of EQ-5D-5L across a variety of conditions [34].
Capability: ICECAP-A. The ICECAP-A instrument was designed to provide a summary
measure of an individual’s capability wellbeing, for use in evaluating the benefits of health and
social care interventions [35]. The ICECAP-A draws on the capability approach in terms of
covering broad determinants of wellbeing through five questions about a person’s capability
(as opposed to their functioning). There is discussion in the philosophical literature around the
capability approach about how best to derive lists of capabilities for use in evaluation. Whilst
some, such as Martha Nussbaum, prefer the notion of a set of capabilities that is fixed across all
contexts [4], others, including Sen himself, see capabilities as more appropriately derived for
particular contexts [10]. The descriptive system for the ICECAP-A instrument was developed
in the UK using qualitative methods [35]. It contains five attributes of “capability wellbeing”
(stability, attachment, autonomy, achievement and enjoyment), each with four levels (http://
www.birmingham.ac.uk/icecap). The attributes aim to capture the capabilities that people
value as distinct from the factors that determine capability (e.g. income, health) [35]. In doing
so, the ICECAP-A measure aims to provide a broader conceptualisation of an individual’s well-
being than solely relying on their health status. This approach to conceptualising capability
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states differ from those who argue for valuing health states through their impact on capability
[15,36].
ICECAP-A UK population values have been developed [37]. The values for ICECAP-A rely
on an approach known as best-worst scaling, that reduces the reliance on preferences used for
measures like the EQ-5D that is challenged by the capability approach [38]. The measure is
anchored at 1 (full capability) and 0 (no capability). Values can range from 0 to 1. The measure
has been validated for the general adult UK population [39].
Condition-Specific Questionnaires. Table 1 summarises the condition-specific question-
naires used for the seven disease groups [40–47]. Global scores for each condition were
required to judge the impact of increased disease severity on individual outcomes (see ‘Data
Analysis’). For asthma, diabetes, depression and heart disease, the global score was obtained
through a simple summation of all items on the questionnaire. For arthritis and cancer the
global score was obtained through summing the subscales. For hearing loss a slightly more
complex calculation was required to account for the particular format of the measure which
records hearing loss both with and without the use of hearing aids. Specific methods for calcu-
lating the global scores for each condition-specific questionnaire are contained in the S1
Appendix. The overall method was tested for validity in relation to clinical severity levels for
the depression questionnaires (the only questionnaires for which clinical cut-offs were avail-
able). Results of this validity test are presented in the S2 Appendix.
Data collection
The survey was conducted online with panel members using a global survey company, CINT
Pty Ltd. The personal and medical details recorded by the company were used to recruit indi-
viduals from the disease groups and from the ‘healthy’ public, i.e. those who did not report any
chronic disease and who obtained a score of at least 70 on a 100 point visual analogue scale
measuring overall health. Quota sampling was conducted to obtain a ‘healthy’ public sample
with age, sex and educational levels that was broadly representative of the general population.
The only quota for disease groups was the total number sought in each disease group irrespec-
tive of age, sex and education. The survey sought a sample of 150 individuals per country in
each disease area and a sample of 300 ‘healthy’ public per country to ensure statistical power
for the initial study [22]. Individuals were asked to complete a relevant disease specific ques-
tionnaire to confirm the existence of the illness and to measure its severity.
The survey was conducted between February and May 2012. Ethics approval was obtained
fromMonash University Human Research Ethics Committee (MUHREC Approval CF11/
1758: 2011 00074). At the start of the survey, a Participant Information and Consent form was
provided. Proceeding with the survey was deemed as consent.
Data Analysis
‘Edit criteria’, based on a comparison of duplicated or similar questions, were used to deter-
mine reliability and validity of the data. Exclusions were based upon several criteria. These
included the existence of multiple IDs (people accessing the system and responding on more
than one occasion); completion of the entire survey in less than 20 minutes—a time which
made it virtually impossible for considered responses; inconsistent responses across a number
of similar or identical questions; and misclassification of the healthy group (indicating very
poor health or the presence of one of the indicated disease areas). Further detail on data collec-
tion and editing prior to the analysis undertaken in this study is provided elsewhere [22].
Statistical analysis was conducted with two main foci; to judge, first, the likely benefit of pre-
venting conditions, and second, the likely benefit of treating (reducing the severity) of conditions.
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First, impacts that would be associated with potential prevention (i.e. avoided losses in health and
capability from preventing onset of disease), were assessed by estimating the differences in health
status and capability for those with conditions, relative to a healthy population. Second, impacts
that might be associated with potential treatment (i.e. improvements in health and capability
from, for example, a movement frommoderate to mild disease severity), were assessed by esti-
mating the differences in health status and capability for different severities of each conditions.
The statistical packages used to analyse the data were Microsoft Excel 2010 and STATA 12.
Potential prevention impact comparing health and capability between disease and
healthy population groups. Descriptive statistics were calculated for both outcomes for the
seven disease groups and the healthy population. Values for capability and health responses
were calculated using UK values.
To measure the differences between the healthy population and each disease group, Cohen’s
d effect size was calculated (see Eq 1). This is the difference in means divided by the standard
deviation of the two populations (e.g. A and B) under consideration [48] and is a useful method
for comparing the same populations across two or more different instruments, even when the
scales of the instruments differ [49]. A small effect size is generally considered to be at least 0.2,
a medium effect size at least 0.5 and a large effect size 0.8 and above [48].
ðmean Amean BÞ
Standard DeviationðAþ BÞ ð1Þ
Table 1. Condition-specific questionnaires used for disease groups.
Arthritis Asthma Cancer Depressiona Diabetes Hearing Problems Heart
Disease
AIMS2‒SF [40] AQLQ–Sydney [41] EORTC QLQ‒C30
[42]
DASS21 [43] Diabetes‒39 [45] APHAB [46] MacNew [47]
26 items 20 items 30 items 21 items 39 items 48 itemsb 27 items
5 sub-scales 4 sub-scales 7 sub-scales 3 sub-scales 5 sub-scales 4 sub-scales; 3 sub-scales
1. Physical 1. Breathlessness 1. Physical functioning 1. Stress 1. Energy and
mobility
1. Ease of
communication
1. Emotional
2. Symptom 2. Mood disturbances 2. Role functioning 2.
Depression
2. Diabetes control 2. Reverberation 2. Physical
3. Affect 3. Social disruption 3. Emotional
functioning
3. Anxiety 3. Anxiety and worry 3. Background noise 3. Social
4. Social
interaction
4. Concerns for
health
4. Cognitive
functioning
4. Social burden 4. Aversiveness
5. Work 5. Social functioning 5. Sexual functioning
6. Pain
7. Fatigue
K10 [44]
10 items
0 sub-scales
AIMS2‒SF, Arthritis Impact Measurement Scales 2‒Short Form; APHAB, Abbreviated Proﬁle of Hearing Aid Beneﬁt; AQLQ-Sydney, Asthma Quality of
Life Questionnaire; DASS21, Depression, Anxiety and Stress Scale 21 item; EORTC QLQ‒C30, European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire‒Core 30; K10, Kessler Psychological Distress Scale 10 item; MacNew heart disease health related quality of life
questionnaire;
a Depression global scores reported using the DASS21.
b APHAB consists of two sections, with hearing aid and without hearing aid consisting of 24 items each
doi:10.1371/journal.pone.0143590.t001
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Potential treatment impact comparing health and capability of different severities of
condition. Individuals in disease groups were then categorised into condition severity levels
by their responses to the condition-specific questionnaires. Not all condition-specific question-
naires have clinical cut-offs for severity levels; therefore a method for standardising the severity
of different conditions and their relative impacts on health status and capability was required.
Global scores for each of the condition-specific questionnaires were calculated and individuals
categorised as having severe (global score below 0.4), moderate (global score between 0.4 and
0.7 inclusive) or mild (global score greater than 0.7) conditions according to this global score.
This method has previously been used for the Arthritis Impact Measurement Scale 2—Short
Form (AIMS2-SF) to compare across studies [50].
Results
6,650 participants were initially included in the survey across the four countries, of whom
1,054 (15.8%) were excluded during the data cleaning exercise. Reasons for exclusion were
inconsistent responses (484; 45.0%), completion in less than 20 minutes (440; 41.0%), misclas-
sification (92; 8.6%) and multiple IDs (58; 5.4%). Additional exclusions were made for this
analysis: 89 respondents from Australia were classified in further disease categories of COPD
and stroke, not collected in other settings; 247 individuals were classified as healthy but had
other conditions outside of those specified; and 12 did not complete the hearing-loss condi-
tion-specific questionnaire in sufficient depth to be classified for the purpose of this analysis. In
total, 5,248 participants were included across Australia, Canada, UK and USA. Table 2 pro-
vides basic socio-demographic information for the different groups included in the analysis
(see S3 Appendix for further country breakdown).
Table 2. Socio-demographic information for included participants (n = 5248).
Sample
Size
Sex Age Groups Country Highest Education Attained
total females 18–
25
25–
34
35–
44
45–
54
55–
64
65+ Aus Can UK US High
School
Diploma,
Certiﬁcate or
Trade
University
Healthy 965 513 122 189 189 181 139 145 200 269 234 262 359 310 296
(18%) (53%) (13%) (20%) (20%) (19%) (14%) (15%) (21%) (28%) (24%) (27%) (37%) (32%) (31%)
Arthritis 640 440 9 38 58 146 227 162 163 139 159 179 230 248 162
(12%) (69%) (1%) (6%) (9%) (23%) (35%) (25%) (25%) (22%) (25%) (28%) (36%) (39%) (25%)
Asthma 579 399 80 137 136 97 87 42 141 138 150 150 179 188 212
(11%) (69%) (14%) (24%) (23%) (17%) (15%) (7%) (24%) (24%) (26%) (26%) (31%) (32%) (37%)
Cancer 577 349 7 23 47 106 217 177 154 138 137 148 197 195 185
(11%) (60%) (1%) (4%) (8%) (18%) (38%) (31%) (27%) (24%) (24%) (26%) (34%) (34%) (32%)
Depression 617 416 64 158 142 148 85 20 146 145 158 168 215 214 188
(12%) (67%) (10%) (26%) (23%) (24%) (14%) (3%) (24%) (24%) (26%) (27%) (35%) (35%) (30%)
Diabetes 641 297 9 46 64 153 226 143 168 144 161 168 221 245 175
(12%) (46%) (1%) (7%) (10%) (25%) (37%) (23%) (27%) (22%) (25%) (26%) (34%) (38%) (27%)
Hearing 589 275 22 51 62 103 158 193 157 146 126 160 194 200 195
Loss (11%) (47%) (4%) (9%) (11%) (17%) (27%) (33%) (27%) (25%) (21%) (27%) (33%) (34%) (33%)
Heart 640 259 24 33 40 109 216 218 149 154 167 170 228 247 165
Disease (12%) (40%) (4%) (5%) (6%) (17%) (34%) (34%) (23%) (24%) (26%) (27%) (36%) (39%) (26%)
Total 5248 2948 337 675 738 1043 1355 1100 1278 1273 1292 1405 1823 1847 1578
(100%) (56%) (6%) (13%) (14%) (20%) (26%) (21%) (24%) (24%) (24%) (27%) (35%) (35%) (30%)
doi:10.1371/journal.pone.0143590.t002
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Potential prevention impact comparing health and capability across
disease and healthy population groups
Depression results in the lowest mean state whether individuals’ outcomes are measured using
the EQ-5D-5L (Fig 1) or the ICECAP-A (Fig 2). For other conditions, however, the difference
relative to healthy individuals varies depending on whether capability or health is measured.
For example, the capability status for individuals with arthritis is close to the capability status
for the healthy population. Yet, the health status of individuals with arthritis is substantially
below the health status of the healthy population and indeed it is closer to the health status for
individuals with depression.
Table 3 reports effect sizes for the mean outcome of disease groups relative to the healthy
population. For both outcome measures, and across all diseases, those with diseases score sig-
nificantly (p<0.05) worse than the healthy population. The absolute effect sizes for the impact
of the conditions are greater for health in all cases than for capability, although the relative dif-
ferences vary considerably. In relation to capability, the effect size for depression is much
greater (1.22) than for all other conditions. Effect sizes for arthritis, asthma, cancer and diabe-
tes and heart disease are similar (0.49 to 0.59) and the effect size in relation to hearing loss is
lower (0.28).
The major conclusion from Table 3, however is that there are notable differences in the pat-
tern of effect sizes across health conditions when measured by health and capability.
Potential treatment impact comparing health and capability for different
severities of condition
Individuals were allocated to mild, moderate or severe categories of the relevant disease group
according to the global scores developed from condition-specific measures (see S3 Appendix
Fig 1. Disease groups and healthy populationmeans for health (assessed by EQ-5D-5L). The error bars represent 95% confidence intervals around the
mean. EQ-5D-5L values generated using cross-walk from EQ-5D-3L UK value set, based on time trade-off [31].
doi:10.1371/journal.pone.0143590.g001
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for country breakdown). Numbers in each category differed by disease group, with four condi-
tions (asthma, cancer, diabetes and heart disease) having the highest concentrations of individ-
uals in the mild category and three (arthritis, depression and hearing loss) having the highest
concentrations of individuals in the moderate category. Across all conditions, the depression
Fig 2. Disease groups and healthy populationmeans for capability (assessed by ICECAP-A). The error bars represent 95% confidence intervals
around the mean. ICECAP-A values generated from original UK population tariff, based on best-worst scaling [37].
doi:10.1371/journal.pone.0143590.g002
Table 3. Effect sizes for disease groups compared to the healthy population for capability (assessed by ICECAP-A) and health (assessed by EQ-
5D-5L).
EFFECT SIZES ORDERING OF CONDITIONS BY
EFFECT SIZE
Capability Health Capability Health
ARTHRITIS 0.55** 1.24*** 3 2
ASTHMA 0.55** 0.82*** 3 6
CANCER 0.54** 1.00*** 5 3
DEPRESSION 1.22*** 1.26*** 1 1
DIABETES 0.59** 0.99*** 2 4
HEARING LOSS 0.28* 0.68** 7 7
HEART DISEASE 0.49* 0.99*** 6 4
*small effect size (0.2+);
**medium effect size (0.5+);
***large effect size (0.8+)
For health there is a different pattern. Although the effect size for depression (1.26) is also highest (and of a similar order to that of capability), the effect
size for arthritis is only very slightly lower (1.24). Effect sizes for cancer, diabetes and heart problems are also high and very similar in size (0.99 to 1.00),
with asthma and hearing loss both having lower effect sizes (0.82 to 0.68).
doi:10.1371/journal.pone.0143590.t003
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category had the highest, and heart disease the lowest, number of individuals categorised as
severe (150 and 45 respectively).
There was little difference in the capability score between individuals with mild arthritis,
hearing loss, or heart disease and the healthy population (Fig 3). Depression is the only disease
group where individuals in the mildly severe group have capability values that differ signifi-
cantly from the healthy population (0.779). In contrast, individuals in all of the mild health cat-
egories have reduced health compared to the healthy population (Fig 4). While the value for
the group with depression is also low (0.748), for other conditions the values range between
0.806 (arthritis) and 0.844 (asthma). The highest of these values is still 0.05 below the healthy
population value.
There also appear to be differences between health and capability for those who have the
most severe conditions. The lowest capability scores are obtained by those with severe depres-
sion (0.484), severe cancer (0.548) and severe arthritis (0.587). The lowest health scores are for
those with severe arthritis (0.257), severe heart disease (0.272) and severe cancer (0.307).
These scores are, again, based on different scales. Apart from individuals with depression,
mildly severe individuals and the healthy group fail to have a small effect size in terms of capa-
bility; for depression the effect size is large (Table 4). Between the severe and moderate catego-
ries, and the moderate and mild categories, effect sizes are all moderate or large, except for
hearing loss. In contrast with capabilities all of the results from the health scale exceed the cut
off score for a small effect size. The differences between the mild and healthy groups have small
or moderate effect sizes for all conditions apart from depression, where the effect size is large.
Fig 3. Disease groupmeans and 95% confidence intervals for capability (assessed by ICECAP-A), by
severity category according to global score derived from condition-specific measures. Population
category sample sizes: Arthritis: mild, n = 132; moderate, n = 437; severe, n = 71; Asthma: mild, n = 344;
moderate, n = 177; severe, n = 58; Cancer, mild: n = 342; moderate, n = 175; severe, n = 60; Depression:
mild, n = 195; moderate, n = 272; severe, n = 150; Diabetes: mild, n = 277; middle, n = 253; severe, n = 111;
Hearing Loss: mild, n = 232; moderate, n = 286; severe, n = 71; Heart disease: mild, n = 378; moderate,
n = 217; severe, n = 45; Healthy population: n = 965.
doi:10.1371/journal.pone.0143590.g003
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Fig 4. Disease groupmeans and 95% confidence intervals for health (assessed by EQ-5D-5L), by
severity category according to global score derived from condition-specific measures. Population
category sample sizes: Arthritis: mild, n = 132; moderate, n = 437; severe, n = 71; Asthma: mild, n = 344;
moderate, n = 177; severe, n = 58; Cancer, mild: n = 342; moderate, n = 175; severe, n = 60; Depression:
mild, n = 195; moderate, n = 272; severe, n = 150; Diabetes: mild, n = 277; middle, n = 253; severe, n = 111;
Hearing Loss: mild, n = 232; moderate, n = 286; severe, n = 71; Heart disease: mild, n = 378; moderate,
n = 217; severe, n = 45; Healthy population: n = 965.
doi:10.1371/journal.pone.0143590.g004
Table 4. Effect size for differences in mean capability (ICECAP-A) and health status (EQ-5D-5L) betweenmild, moderate and severe impairment in
seven diseases.
Effect Sizes Arthritis Asthma Cancer Depression Diabetes Hearing Loss Heart Disease
MILD VERSUS HEALTHY
Capability -0.13 0.17 0.07 0.82*** 0.12 0.01 -0.07
Health 0.72** 0.40* 0.63** 1.06*** 0.64** 0.48* 0.68**
Sample size 1,097 1,309 1,307 1,160 1,242 1,197 1,343
MODERATE VERSUS MILD
Capability 0.63** 0.79** 0.84*** 0.81*** 0.60** 0.36* 1.07***
Health 0.97*** 1.01*** 1.17*** 0.68** 0.75** 0.30* 1.07***
Sample size 569 521 517 467 530 518 595
SEVERE VERSUS MODERATE
Capability 1.31*** 0.56** 1.19*** 0.65** 0.65** 0.27* 1.01***
Health 1.62*** 0.74** 1.26*** 0.81*** 0.73** 0.44* 1.30***
Sample size 508 235 235 422 364 357 265
Categories on a 1–0 mild severe scale for each condition-speciﬁc questionnaire where mild, > 0.7; moderate, 0.4–0.7; severe.<0.4. Effect sizes:
small (*) = 0.2+;
medium effect size (**) = 0.5+;
large effect size (***) = 0.8+.
Reported sample size is combination of two groups under consideration. Sensitivity analysis using US weights for EQ-5D-5L are reported in S4 Appendix.
doi:10.1371/journal.pone.0143590.t004
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Between the severe and moderate categories, and the moderate and mild categories, effect sizes
are all moderate or large, except for the case of hearing loss where they are again small.
Discussion
The findings reported here show that major diseases are associated with relatively different
impacts on health and capability. This indicates that a focus on capability outcomes, rather
than with health status, would alter the relative importance of preventing and treating different
conditions. In particular, two findings from this research are significant. The first is the rela-
tively greater effect sizes on the capability scale for individuals with depression as compared
with other disease groups. The second is the insignificant difference in effect sizes for capabili-
ties between individuals with mild conditions and the healthy population for all of the disease
groups apart from depression.
To date, empirical comparisons of the capability approach with respect to health are rela-
tively limited to single disease contexts [20,51–56], reflecting the lack of large datasets across
multiple conditions. This paper therefore provides the first evidence for the possibility that dif-
ferent inferences may be drawn about the relative value of treating and preventing different
conditions across the health service when focusing on improving capability wellbeing rather
than health status.
There are, however, a number of limitations. First, the MIC dataset is cross-sectional, and
inferences about the impact of diseases are made by comparing disease groups and healthy
members of the general population. This is an inevitable limitation of research until time series
data becomes available. Second, the global scoring system used for categorising individuals pro-
duced a consistent method of grouping across disease areas, but is inescapably somewhat arbi-
trary as there is no recognised method of classification for all diseases. The need for cross
disease group analyses highlights the importance of generic instruments such as EQ-5D-5L
[29], and ICECAP-A [35]. It is important to acknowledge that the ICECAP-A is one interpre-
tation of measuring capability, and other measures of capability have also been recently devel-
oped [57–64]. Finally both instruments were scored using UK values as only UK values exist
for ICECAP-A. Values are available for EQ-5D-5L for the USA but not for Australia or Can-
ada. The US values for EQ-5D-5L were employed in a separate analysis but resulted in almost
identical findings (see S4 Appendix).
Despite these limitations, the present study indicates how interventions for different health
conditions might be prioritised under a different evaluative paradigm and there are a number
of implications of this. First, with effective interventions, preventing morbidity from an average
case of depression would have a significantly larger impact on capability wellbeing than pre-
venting morbidity in any of the other disease areas in this study. The relative priority given to
effective treatments for depression would therefore rise under this paradigm. Second, the find-
ings suggest that the impact on capability wellbeing of mild disease is generally very small. This
suggests that, by contrast with evaluations based upon health there may be little benefit from
interventions focused on preventing mild morbidity. The exception to this is depression, where
even mild disease appears to have a clear impact on an individual’s capability. Prioritising on
the basis of capability, therefore, suggests that greater priority would go to those with depres-
sion and those with severe or moderate illness than under a paradigm where the evaluative
focus was on health status.
The results suggest a number of avenues for further research. First, more information is
needed both from time series and intervention studies. Second, these findings relate only to
morbidity and not mortality. It has been estimated that around half the burden of poor health
in one developed country setting, Australia, arises from morbidity rather than premature
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mortality [23]. For some of the conditions explored here there is very high premature mortal-
ity, with around one third of the burden of premature mortality terms arising from cancer and
a similar amount from heart disease [23]. A comprehensive system of prioritising must, of
course, also take account of this. Third, alternative measures of both health and capability, and
indeed health capability [8,65] could be used to assess the extent to which the results reported
here are influenced by the particular choices of health status and capability instruments. The
EQ-5D values are particularly sensitive to pain and physical problems [22]. Other instruments
with a greater psycho-social content might result in different conclusions. Conversely a per-
son’s perception of their capability in different areas of their life may be affected by their mood
[66]. It would also be worth exploring further if depression affected capability similarly across
different capability instruments. Depression’s large relative impact on capability may also
influence individual’s capability with multiple morbidities, so this warrants further scrutiny in
studies that collect data on more than one condition. Finally, a choice between prioritising on
the basis of health or on the basis of capability wellbeing is ultimately a normative question.
Societal views about such prioritisation methods should be sought.
To conclude, this study highlights the potential importance of the choice of outcome for the
allocation of resources in the health sector. The suggestion from this work is that a shift from a
focus on health to a broader focus on capability wellbeing could result in changes both to the
disease areas that are given priority and the priority given to those with different levels of sever-
ity of the same disease.
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